Values assessments total cost assessment

Medical intervention costs can be normalized to assess total costs using quality-adjusted life years (QALYs) gained by the intervention. The use of a QALY approach to treatment of critically ill patients with ARP indicates that treating these patients is very expensive relative to other common medical interventions. For example, using 2001 cost values, the treatment of critically ill ARF patients cost per QALY was 168,711, compared to treatment of acute myocardial infarction cost per QALY of 45,000, and the routine treatment of hypertension... 

The above analysis is somewhat oversimplified and is considered an Incomplete assessment of the existing environmental problems caused by pesticides. Again, it must be emphasized that there is no completely satisfactory way to summarize all of the environmental and social costs in terms of dollars. For example, it is impossible, if not unethical to place a monetary value on human lives either lost, diseased, or disabled because of pesticide use. It is equally difficult to place a monetary value on total wildlife losses. Good health, and Indeed life itself have no price tag. 

Question four addresses one of the most important issues in the critical assessment of economic analyses, that is, the issue of identification and inclusion/exclusion of resources. As discussed in the previous section, the actual scope of the resources included should match the (stated) perspective of the analysis. It is important to note that it is not always possible to measure and value all the costs and consequences of the alternatives however, a comprehensive list of the most important and relevant ones should be provided, along with justification for any major omissions. For example, a new drug has several side effects with similar rates of occurrence. One side effect results in a transient cough, another results in a Gl bleed. Given the scope of the total costs/resources involved, an economic analysis of this drug could probably justify non-inclusion of the treatment costs associated with the cough. However, because of the significant impact of even one hospitalisation, the costs associated with the Gl bleed must be included. 

Based on previous studies the expected total costs C, , may be generally considered as the sum of the expected initial costs, costs of inspections, maintenance, and failure consequences. The decision parameter x to be optimized in the assessment may influence resistance, serviceability, durability, maintenance, inspections upgrade strategies etc. In the present study the decision parameter is assumed to concern the initial costs only while the other costs (inspections, maintenance, future repair etc.) are independent of x (and excluded from the optimization). Moreover the benefits related to use of the structure that in general should be considered in the optimization are not affected by value of the decision parameter. These are reasonable assumptions in case of solar panels. 

Many economic performance indicators have been proposed to assess the economic performance of a SC network design. The most traditional indicators are profit, net present value (NPV), and total cost. However, other more holistic measures have been proposed which take into account the dynamic change of net working capital (see Chap. 2). Similarly to the SC operations model, the reader is referred to Sect. 5.3.2 where the equations belonging to the economic model are found. Notice that for this case, the CO2 emissions trading must be taken into account in the economic model. 

The maintenance costs and the initial cost are frequently assessed as the Net Present Value (N) which represents the sum of money that must be set aside to now cover both initial and maintenance costs over the total life required. 

The benefits discussed earlier fall into two areas the time-value of information and the improvement in laboratory productivity. Assessing the benefits of the time-value of information requires examination of the total process through which that information will be used. For example, using data such as the turnaround time, rate at which material is produced, its value, and losses attributable to scrap or rework, one can estimate the savings. Similarly, knowing the average labor, overhead, and General and Administrative (G A) costs allows one to convert productivity improvements in the lab to dollar values of equivalent labor made free for more productive uses. 

One way of assessing the commercial viability for a new product is to subtract the total development costs from the potential market share value. The potential market share value is estimated by multiplying the percentage of the potential number of patients by the potential commercial price for the new product. An alternative approach is to do the calculations based on the cost of the product or one course of treatment ... 

At present there is no question that the propylene shortage is a reality, and there is need to assess the potential as well as the actual sources of propylene. In this respect, the price that propylene should seek will provide a frame of reference. Consider that the gasoline value of propylene equals approximately 2.8 cents/lb (12.5 cents/gal -s- 4.35 lb/gal) and that propylene recovery costs should not exceed 0.2 cents/lb. The total—3.0 cents/lb—is a break-even area for a refiner. He will be sorely tempted to release propylene above this price and satisfy gasoline commitments by other means. The exact price, of course, will vary for each refinery and will be a function not only of its raw materials vs. sales picture but also of its accounting techniques. The 3.0 cents/lb figure could vary by as much as 0.5 cents/lb, and will depend on surplus of refining capacity (pool octane), isobutane, refining processes in place, etc. 

---